United States securities and exchange commission logo




                                                                                
                          March 1, 2024

       Alex Sapir
       President and Chief Executive Officer
       Fulcrum Therapeutics, Inc.
       26 Landsdowne Street
       Cambridge, Massachusetts 02139

                                                        Re: Fulcrum 
Therapeutics, Inc.
                                                            Registration 
Statement on Form S-3
                                                            Filed February 27, 
2024
                                                            File No. 333-277419

       Dear Alex Sapir:

              This is to advise you that we have not reviewed and will not 
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for 
acceleration. We remind you
       that the company and its management are responsible for the accuracy and 
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of 
action by the staff.

                                                        Please contact Cindy 
Polynice at 202-551-8707 with any questions.



                                                                                
                          Sincerely,

                                                                                
                          Division of Corporation Finance
                                                                                
                          Office of Life Sciences
       cc:                                              Marianne Sarrazin, Esq.